Spironolactone Tablet
Product Images NDC 71610-742

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Spironolactone (NDC 71610-742). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 25 mg (71610 0742 45)

SPIRONOLACTONE 25 mg oral tablets in a bottle containing 45 tablets. The white label displays product name, strength, NDC 71610-0742-45, and handling instructions including storage at 20-25 degrees Celsius and protection from light and moisture. Manufactured by Frontida BioPharm, Philadelphia, PA and labeled by Aphena Pharma Solutions - Tennessee, LLC.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Structure (Spironolactone 01)

Chemical structure diagram of spironolactone, showing its steroidal core with attached functional groups including a lactone ring and thioester moiety.*

FDA Label Image

Figure 1 (Spironolactone 02)

A Kaplan-Meier survival probability curve comparing Spironolactone with Placebo over a time period of up to 48 months. The y-axis represents probability, and the x-axis represents months. The graph shows higher survival probability for Spironolactone compared to Placebo, with a statistically significant difference (log-rank p < 0.001).*

FDA Label Image

Figure 2 (Spironolactone 03)

A forest plot chart illustrating hazard ratios (HR) with 95% confidence intervals (CI) for subgroups analyzed in a clinical study comparing Spironolactone and placebo. Subgroups include age, sex, race, LVEF percentage, heart failure type, NYHA class, diabetes status, serum creatinine, creatinine clearance, potassium levels, digoxin use, ACE inhibitor use, and beta blocker use. The x-axis ranges from 0.2 to 1.4, indicating the effect direction: left favors Spironolactone, right favors placebo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.